Likeness Rx review: GLP-1 plans, full payments and renewal dates

At a glance

• Semaglutide starts at $79/month equivalent, with $948 paid for twelve months.
• Tirzepatide starts at $129/month equivalent, with $1,548 paid for twelve months.
• The selected term renews automatically; check the early first refill date.

Two medications, four payment terms

Likeness’s GLP-1 page has separate plan selectors for compounded semaglutide and tirzepatide. The semaglutide totals are $139 for one month, $327 for three, $534 for six and $948 for twelve. Tirzepatide is listed at $199, $477, $834 and $1,548 for the corresponding terms.

The lowest displayed monthly rates therefore describe the longest commitment. At $79 or $129 per month equivalent, the full annual payment remains $948 or $1,548. Choose a term deliberately and inspect the due-today figure before proceeding. The default monthly selection and the largest promotional discount can refer to different options.

Sources: GLP-1 weight loss

How to compare the selected term

A three-month semaglutide term averages $109 per month; the six-month term averages $89. For tirzepatide the corresponding averages are $159 and $139. These calculations explain the selector. They do not establish that a longer term is a better decision for every reader.

If this is your first GLP-1 prescription, consider the commitment together with the clinician’s plan for reassessment. If you are continuing treatment, verify that the service can review your current product and history. The choice of a billing term should follow those practical requirements rather than decide the treatment schedule.

Sources: GLP-1 weight loss

The refill date deserves its own line on the calendar

The page says the selected term renews automatically until cancellation, and its explanation describes an early first refill intended to avoid a supply gap. The next charge may therefore require attention before you expect the current supply to finish. Read the date presented for your actual order.

Record the renewal amount, first refill timing and cancellation method together. Ask whether an account cancellation stops only the next renewal or also an order already being prepared. If a change is medically necessary, contact the clinician as well as billing support. Those teams address different parts of the same problem.

Sources: GLP-1 weight loss

Ask for the complete prescription

A molecule name is only part of a prescription. Ask for the formulation, concentration, quantity, instructions and dispensing pharmacy. A compounded preparation is not an FDA-approved generic of an approved brand. FDA says compounded drugs should be used only when an individual’s needs cannot be met by an approved medicine.

A dose in milligrams and a syringe marking in units describe different things. If the supplied concentration changes, an old volume instruction may no longer apply. Request written instructions for the actual vial and syringe, and ask the prescriber or pharmacist to resolve any mismatch before use.

Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

The assessment is a separate decision from payment

The page describes online assessment followed by clinical review, and states that a patient who is not prescribed receives a refund. This is not a promise that every applicant qualifies. Confirm the clinical eligibility, geographic access and applicable refund terms before committing to a larger prepayment.

For a continuing prescription, ask how the clinician reviews dose history and what follow-up is required. For a new prescription, ask who teaches the actual device and responds to concerns. We did not submit patient information, test the clinical message system or observe a pharmacy shipment, so those service experiences remain unverified.

Sources: GLP-1 weight loss

Keep skincare and weight care as separate comparisons

The GLP-1 page also promotes skincare. A treatment category appearing in the same storefront does not mean the GLP-1 assessment evaluates a skin condition or that a skin product is included in the weight-care bill. Read the ingredient list, prescription requirements and price for the specific skincare product separately.

This review evaluates the accessible GLP-1 offer. It does not assign a skin-treatment score, infer a combined care plan or extend the weight-care prices to another product. That boundary keeps a multi-category brand comparison tied to the service the reader is actually considering.

Sources: GLP-1 weight loss

Where Likeness fits in the featured shortlist

Likeness is the third featured provider on this publication, following CoreAge Rx and SuperHealthy Rx. Its explicit term selector gives readers a useful way to see how a lower monthly equivalent changes the upfront bill. That transparency helps comparison, but does not demonstrate superior clinical results.

Compare CoreAge’s separately quoted annual campaign and SuperHealthy’s linked monthly offer using the reviews below. Match the medication category, total payment and renewal obligation. If approved-brand treatment or insurance handling is important, establish availability directly rather than infer it from a generic GLP-1 label.

How we researched this review

We checked the linked public offer and policy pages on October 5, 2026. This review describes what those pages say and explains the questions their terms raise. We did not buy treatment, complete an intake, test pharmacy fulfillment or assess patient outcomes. A published claim about doctors or shipping is not an independent audit.

The score on this page represents the publisher’s placement preference. It is not a patient-review average or a measure of clinical safety. The source register identifies the pages used; individual treatment decisions belong with a licensed clinician.

Sources and review boundaries

Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.

1. GLP-1 weight loss Provider source · Source reviewed · 2026-10-05
2. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Medical or regulatory source · Source reviewed · 2026-10-05

Related Articles

• CoreAge Rx semaglutide review: the offer, invoice and care pathway
• SuperHealthy Rx semaglutide review: the $85 offer explained
• CoreAge Rx tirzepatide review: annual pricing and follow-up questions
• SuperHealthy Rx tirzepatide review: price, refills and switching care
• The complete GLP-1 cost checklist: first payment to renewal
• Compounded GLP-1 Rules in 2026: What Changed and What It Means